Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,252.00
Bid: 12,250.00
Ask: 12,252.00
Change: 134.00 (1.11%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

Wed, 03rd Jan 2024 16:52

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

The FTSE 100 index closed down 39.19 points, 0.5%, at 7,682.33. The FTSE 250 ended down 185.40 points, 1.0%, at 19,326.40, and the AIM All-Share closed down 7.40 points, down 1.0%, at 754.15.

The Cboe UK 100 ended down 0.4% at 766.89, the Cboe UK 250 closed down 1.1% at 16,780.39, and the Cboe Small Companies ended down 0.6% at 14,860.40.

"The FTSE 100 marked its 40th birthday with a celebration more akin to a quiet pint in an empty pub than anything more befitting of a major landmark," said AJ Bell analyst Russ Mould.

There was little to celebrate on Wednesday, with investors cautiously eyeing the US Federal Reserve minutes. They are out at 1900 GMT.

Analysts are hoping to find some context around the Federal Reserve's dovish pivot in December.

There was also some US manufacturing data, as well as the latest jobs opening reading to digest on Wednesday afternoon.

The US manufacturing sector continued to contract, but at a slightly slower rate. The Institute for Supply Management's manufacturing purchasing managers index rose to 47.4 in December, from 46.7 in November. According to FXStreet, the figure was expected to be slightly lower at 47.1.

"The overall economy continued in contraction for a third month after one month of weak expansion preceded by nine months of contraction and a 30-month period of expansion before that," noted Timothy Fiore, chair of the ISM.

Also on Wednesday, the US Bureau of Labor Statistics published the number of job openings in November.

The number of job openings decreased to 8.790 million on the last business day in November from 8.852 million a month earlier. This was below FXStreet consensus of 8.85 million.

Stocks in New York were lower at the London equities close, with the DJIA down 0.7%, the S&P 500 index down 0.6%, and the Nasdaq Composite down 0.8%.

In European equities on Wednesday, the CAC 40 in Paris ended down 1.8%, while the DAX 40 in Frankfurt ended down 1.5%.

The pound was quoted at USD1.2646 at the London equities close Wednesday, higher compared to USD1.2620 at the close on Tuesday. The euro stood at USD1.0915 at the European equities close Wednesday, down against USD1.0955 at the same time on Tuesday. Against the yen, the dollar was trading at JPY143.50, higher compared to JPY141.74 late Tuesday.

In London, Tesco and Sainsbury's both added 1.6%. Meanwhile, Marks & Spencer rose 2.2%

The UK grocery sector had its busiest festive period since the onset of the Covid-19 pandemic four years ago, numbers from Kantar showed, while price inflation worries for consumers abated.

Kantar said grocery sales in the 12 weeks to December 24 rose 6.9% to GBP36.45 billion from GBP34.10 billion a year before. In the final four weeks of that period alone, sales totalled GBP13.7 billion.

Annual grocery price inflation in December eased to 6.7% from 9.1% in the four weeks to November 26. December's figure was the tamest level since April 2022, and Kantar said it was the sharpest monthly slowdown it has ever recorded.

This has prompted interest rate talk in the UK. AJ Bell's Mould said that the latest data "will add grist to the mill on calls for the Bank of England to consider interest rate cuts."

However, in the past few weeks, there has also been tension in the Red Sea which has prompted inflation worries as oil prices continue to push higher.

Brent oil was quoted at USD78.13 a barrel at the London equities close Wednesday, up from USD77.75 late Tuesday.

On Wednesday, oil firms BP and Shell were up 0.3% and 0.9%, respectively.

Elsewhere on London's FTSE 100, GSK rose 2.7%

Jefferies raised GSK to 'buy' from 'hold'.

In the FTSE 250, Wizz Air lost 4.2%, after the Budapest-based airline said it carried 5.0 million passengers in December, up 19% from 4.2 million the year prior. Capacity for the month was 22% higher at 6.0 million seats, compared to 4.9 million seats in December 2022.

Its load factor fell year-on-year, however, to 82.1% from 84.5%.

Ryanair, meanwhile, said it carried 12.5 million passengers in December, up 8.7% from 11.5 million in the corresponding month last year. Its load factor fell by one point to 91% from 92% the year before.

Ryanair added that it operated 72,500 flights in December, but noted that over 900 flights were cancelled due to the Israel-Gaza conflict.

Shares were down 4.8% in Dublin.

On AIM, C4X Discovery surged 29%, after the drug discovery company said it received a USD11.0 million milestone payment from FTSE 100-listed pharmaceutical firm AstraZeneca, following trials of the C4X respiratory disease therapy treatment.

The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November.

In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.

AstraZeneca shares closed down 0.6%.

Gold was quoted at USD2,038.89 an ounce at the London equities close Wednesday, down against USD2,064.66 at the close on Tuesday.

In Thursday's UK corporate calendar, there are trading statements from M&C Saatchi, Mattioli Woods, and Next.

The economic calendar for Thursday has there are a slew of service PMI readings from China, the eurozone, the UK and the US.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.